Skip to search formSkip to main contentSkip to account menu

ME1036

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
ME1036, a novel parenteral carbapenem, was developed for the treatment of MRSA and vancomycin-intermediate S. aureus (VISA). A… 
2011
2011
We have correlated the binding affinities of ME1036, a carbapenem, to the penicillin-binding proteins (PBPs) from Streptococcus… 
2009
2009
fer of such strains from animal to meat products, e.g. during slaughtering. The characterization and comparison of plasmids in… 
2009
2009
1. Sahm D, Draghi D, Thornsberry C. Activity of ME1036, a novel anti-MRSA carbapenem, against Gram-positive and Gram-negative… 
2005
2005
ABSTRACT The efficacy of ME1036, a novel parenteral carbapenem, was compared with that of vancomycin by using a rabbit model of… 
2005
2005
We investigated the antibacterial activities of 19 beta-lactams against three recombinant bacterial strains, in which three… 
2004
2004
ME1036, formerly CP5609, is a novel parenteral carbapenem with a 7-acylated imidazo[5,1-b]thiazole-2-yl group directly attached…